Infiltration of CD8+ T cells, a key player in anti-tumor immunity, was significantly associated with a longer DFS, suggesting that necroptosis-based cancer therapy could be a potential therapeutic option for CCA patients, improving the clinical outcomes through activation of the immune system. The gene discussed is CD8A; the disease is cholangiocarcinoma.